Hits: 92 · No unexpected safety findings and no relevant safety differences between zilucoplan and placebo were identified · Phase 3 headline results for generalized myasthenia gravis (gMG) are unchanged expected in Q4 2021
BRUSSELS, Belgium I April 22, 2021 I Based on the initial results of a Phase 2 study investigating
zilucoplan in immune-mediated necrotizing myopathy (IMNM), UCB today announced that UCB has decided to not move forward with its IMNM development program.
The phase 2 study with
zilucoplan, a peptide inhibitor of complement component 5 (C5), in immune-mediated necrotizing myopathy (IMNM) did not show a meaningful effect of
zilucoplan for people living with IMNM. No unexpected safety findings and no relevant safety differences between